I47.1

Supraventricular tachycardia

## Clinical Overview Paroxysmal Supraventricular Tachycardia (PSVT) is a clinical syndrome characterized by the sudden onset and offset of rapid heart rhythms originating from atrial or atrioventricular nodal tissue. These arrhythmias typically manifest as a narrow QRS complex tachycardia on an electrocardiogram (ECG), with heart rates usually ranging between 150 and 250 beats per minute. PSVT is not a single disease entity but rather a group of arrhythmias, most commonly encompassing Atrioventricular Nodal Reentrant Tachycardia (AVNRT), Atrioventricular Reentrant Tachycardia (AVRT) involving an accessory pathway, and Atrial Tachycardia. ### Pathophysiology The most frequent mechanism underlying PSVT is re-entry, which requires the presence of two physiologically distinct pathways with different conduction velocities and refractory periods. In AVNRT, these pathways (slow and fast) are located within or adjacent to the AV node. In AVRT, the circuit involves the normal conduction system and an extra-nodal accessory pathway (such as the Bundle of Kent in Wolff-Parkinson-White syndrome). When a premature atrial or ventricular beat occurs at a critical moment, it can trigger a self-sustaining circular electrical impulse. Less commonly, PSVT is caused by triggered activity or enhanced automaticity in a focal group of atrial cells. ### Diagnostic Criteria and Evaluation The gold standard for diagnosis is a 12-lead ECG during an episode, which typically shows a regular, narrow-complex tachycardia (QRS < 120 ms). P-waves may be buried within the QRS complex, visible immediately after (in AVNRT), or separated by a short PR interval. Clinical evaluation includes a thorough history to identify triggers (caffeine, stress, physical exertion) and physical examination. In patients with infrequent episodes, ambulatory monitoring (Holter or event recorders) is necessary. An Echocardiogram is often performed to rule out structural heart disease, although most PSVT patients have structurally normal hearts. ### Management and Standard of Care Acute management focuses on termination of the arrhythmia. Vagal maneuvers, such as the Valsalva maneuver or carotid sinus massage, are first-line interventions. If unsuccessful, intravenous adenosine is the pharmacological treatment of choice due to its short half-life and potent AV-nodal blocking effects. For long-term management, patients may be managed conservatively, with AV-nodal blocking agents (beta-blockers or non-dihydropyridine calcium channel blockers), or through catheter ablation. Radiofrequency catheter ablation has become the definitive therapy for most symptomatic PSVT patients, offering success rates exceeding 95% with a low risk of complications.

Clinical Symptoms

  • Palpitations
  • Dizziness
  • Shortness of breath
  • Chest discomfort
  • Lightheadedness
  • Syncope (rare)
  • Polyuria
  • Neck pulsations (frog sign)
  • Anxiety
  • Fatigue

Common Causes

  • Atrioventricular nodal re-entry
  • Accessory atrioventricular pathways (e.g., WPW)
  • Caffeine consumption
  • Excessive alcohol use
  • Psychological stress
  • Electrolyte imbalances
  • Hyperthyroidism
  • Stimulant use
  • Valvular heart disease
  • Myocardial ischemia

Documentation & Coding Tips

Distinguish between Paroxysmal and Permanent SVT

Example: Patient with recurrent, paroxysmal supraventricular tachycardia (I47.1) manifesting as sudden-onset palpitations. Episodes occur 2-3 times per month, lasting 15 minutes, responsive to vagal maneuvers. Documentation includes history of compensated HFrEF (I50.22), which increases risk adjustment complexity due to pharmacological management constraints.

Billing Focus: Identify the paroxysmal nature and frequency to support medical necessity for prolonged monitoring.

Document Specific SVT Subtypes for Accuracy

Example: Assessment: Supraventricular tachycardia (I47.1) specifically suspected as Atrioventricular Nodal Reentrant Tachycardia (AVNRT). Currently stable but frequent breakthroughs on Metoprolol. Plan: Electrophysiology (EP) study to confirm mechanism and potential ablation. Patient has comorbid Type 2 Diabetes with neuropathy (E11.40), elevating the risk of cardiovascular autonomic dysfunction.

Billing Focus: Specificity of the tachycardia mechanism to justify specialized EP procedures.

Clarify the Presence of Accessory Pathways

Example: Patient with known Wolff-Parkinson-White syndrome (I45.6) presenting with acute SVT (I47.1). Note indicates delta waves on EKG. The documentation of the underlying pre-excitation syndrome is critical for billing the complex ablation procedure and risk adjusting for higher mortality risk.

Billing Focus: Linkage between the syndrome (I45.6) and the current manifestation (I47.1) for high-complexity coding.

Include Hemodynamic Stability and Symptoms

Example: Acute SVT (I47.1) at 180 bpm with associated presyncope (R42) and mild chest pain (R07.9). Patient is currently normotensive but requires IV Adenosine. Associated with long-standing essential hypertension (I10) and morbid obesity (E66.01, BMI 42).

Billing Focus: Symptoms like presyncope and chest pain justify the 'Acute' nature and emergency-level intervention billing.

Document the Triggering Factors and Associated Conditions

Example: SVT (I47.1) occurring post-thoracic surgery. This is a new-onset atrial tachycardia. Note specifies this is not Atrial Fibrillation. Patient also has COPD (J44.9) which limits use of non-selective beta-blockers, necessitating calcium channel blocker therapy for rate control.

Billing Focus: Clear differentiation from Atrial Fibrillation (I48.x) to ensure correct E/M level and procedural coding.

Relevant CPT Codes

Related Diagnoses

Hierarchy